Borders drug outfit seeks approval for rickets treatment

Share this article
0
Have your say

Kyowa Kirin International (KKI), the Borders-based drug developer formerly known as ProStrakan, is seeking European marketing authorisation for a treatment aimed at the most common inherited cause of rickets.

The Galashiels firm, owned by Japan’s Kyowa Hakko Kirin, said the move marks a “major milestone” for the company as the new drug, dubbed KRN23, is the first in its pipeline of treatments to reach the stage of seeking European approval.

KKI chief Tom Stratford said there are no currently approved treatments that target the underlying cause of XLH, a genetic disorder that can trigger rickets. Picture: Greg Macvean

KKI chief Tom Stratford said there are no currently approved treatments that target the underlying cause of XLH, a genetic disorder that can trigger rickets. Picture: Greg Macvean

Rickets, which can cause bone pain, poor growth and deformities such as bowed legs and curvature of the spine, is most commonly linked to a lack of calcium or vitamin D.

READ MORE: Increase in rickets linked to overuse of sunscreen

However, it can also be triggered by X-linked hypophosphatemia (XLH), a rare genetic disorder that affects about one in 20,000 people, whose kidneys treat phosphorus as a waste product instead of returning enough of it to the circulation for use by bones and teeth.

KKI chief executive Tom Stratford said: “XLH is a debilitating condition which causes long-term pain and distress among sufferers and for which there are no currently approved treatments that target the underlying cause.

“As part of Kyowa Hakko Kirin, we strive to contribute to the health and wellbeing of people around the world through advances in life sciences and technologies. The acceptance of this filing brings us one step closer to addressing the unmet medical needs of patients who suffer from XLH.”

READ MORE: ProStrakan in $70m deal for constipation treatment

KKI is collaborating with Ultragenyx Pharmaceutical, a US-based firm that targets rare genetic diseases, in the development and commercialisation of KRN23. A decision from the European Medicines Agency’s committee for medicinal products for human use is expected in the second half of the year.

Ultragenyx chief executive Emil Kakkis said: “Based on the positive results from multiple studies in paediatric and adult patients with XLH, we are pursuing conditional marketing authorisation in order to accelerate access to this therapy for patients.”

Click here to ‘Like’ The Scotsman Business on Facebook

Back to the top of the page